Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 12, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Global R&D, CSO | June 16, 2014 | June 18, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 16, 2014 · Filed June 18, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,017 |
Reported balance
After 2014-06-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2014-06-16 · Exercise / conversion · Acquired 7,500 · Balance 151,017 |
| Common StockSEC Table I · non-derivative | Direct | 146,614 |
Reported balance
After 2014-06-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2014-06-16 · Sale · Disposed 4,403 · Balance 146,614 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96). F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 145,114 |
Reported balance
After 2014-06-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2014-06-16 · Sale · Disposed 1,500 · Balance 145,114 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86). |
| Common StockSEC Table I · non-derivative | Direct | 143,517 |
Reported balance
After 2014-06-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2014-06-16 · Sale · Disposed 1,000 · Balance 143,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99). |
| Common StockSEC Table I · non-derivative | Direct | 144,517 |
Reported balance
After 2014-06-16 transaction · row 4
1 source rowRow 4 · 2014-06-16 · Sale · Disposed 597 · Balance 144,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.16 · Expires 2018-07-23 | Direct | 15,500 |
Reported balance
After 2014-06-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2014-06-16 · Exercise / conversion · Disposed 7,500 · Balance 15,500 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 4,770 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,770 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 5,568 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 5,568 |
| Common StockSEC Table I · non-derivative | IndirectCommon stock held in trust | 15,233 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 15,233 F7: Common stock held in grantor retained annuity trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96).
F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86).
F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95).
F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99).
F7: Common stock held in grantor retained annuity trust.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2014 Filed Feb 7, 2014 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 51,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008356 · doc4.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 17,250 | $0.01 | $172.50 |
DisclosureSEC source: 0001209191-14-008356 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,750 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| January 15, 2014 Filed Jan 17, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-14-003731 · doc4.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,750 Underlying: Common Stock · 7,500 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| January 15, 2014 Filed Jan 17, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,500 | $78.67 | $590,025.00 |
DisclosureSEC source: 0001209191-14-003731 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,500 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $78.67 (range $78.29 to $79.05). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2014 Filed Jan 17, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $28.84 | $216,300.00 |
DisclosureSEC source: 0001209191-14-003731 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2013 Filed Dec 17, 2013 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-13-057361 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,250 Underlying: Common Stock · 4,500 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| December 16, 2013 Filed Dec 17, 2013 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,100 | $65.42 | $137,382.00 |
DisclosureSEC source: 0001209191-13-057361 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,500 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $65.42 (range $64.95 to $66.46). Read SEC document |
| December 16, 2013 Filed Dec 17, 2013 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,400 | $64.40 | $347,760.00 |
DisclosureSEC source: 0001209191-13-057361 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,600 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $64.40 (range $63.94 to $64.83). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 16, 2013 Filed Dec 17, 2013 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $28.84 | $216,300.00 |
DisclosureSEC source: 0001209191-13-057361 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2013 Filed Dec 12, 2013 22:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,900 | $65.48 | $189,892.00 |
DisclosureSEC source: 0001209191-13-056698 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,500 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $65.48 (range $65.06 to $65.91). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-13-053081 · doc4.xml · derivative · entry 9 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,750 Underlying: Common Stock · 4,500 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-13-053081 · doc4.xml · derivative · entry 8 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,200 | $63.12 | $138,864.00 |
DisclosureSEC source: 0001209191-13-053081 · doc4.xml · nonDerivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,400 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $63.12 (range $63.02 to $63.26). Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,200 | $62.62 | $263,004.00 |
DisclosureSEC source: 0001209191-13-053081 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,600 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $62.62 (range $62.00 to $62.98). Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $61.58 | $67,738.00 |
DisclosureSEC source: 0001209191-13-053081 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,800 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $61.58 (range $61.00 to $61.97). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,000 | $18.93 | $56,790.00 |
DisclosureSEC source: 0001209191-13-053081 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,500 | $28.84 | $129,780.00 |
DisclosureSEC source: 0001209191-13-053081 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2013 Filed Oct 17, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-13-048645 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 7,500 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| October 15, 2013 Filed Oct 17, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 666 | $73.85 | $49,184.10 |
DisclosureSEC source: 0001209191-13-048645 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,400 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $73.85 (range $73.67 to $74.16). Read SEC document |
| October 15, 2013 Filed Oct 17, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,834 | $73.19 | $500,180.46 |
DisclosureSEC source: 0001209191-13-048645 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,066 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $73.19 (range $72.66 to $73.65). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 15, 2013 Filed Oct 17, 2013 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $18.93 | $141,975.00 |
DisclosureSEC source: 0001209191-13-048645 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2013 Filed Sep 17, 2013 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-13-044599 · doc4.xml · derivative · entry 8 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 7,500 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| September 16, 2013 Filed Sep 17, 2013 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $79.08 | $15,816.00 |
DisclosureSEC source: 0001209191-13-044599 · doc4.xml · nonDerivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,400 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 16, 2013 Filed Sep 17, 2013 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,320 | $78.38 | $103,461.60 |
DisclosureSEC source: 0001209191-13-044599 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,600 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $78.38 (range $78.03 to $78.89). Read SEC document |
| September 16, 2013 Filed Sep 17, 2013 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,895 | $77.44 | $224,188.80 |
DisclosureSEC source: 0001209191-13-044599 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,920 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $77.44 (range $76.97 to $77.96). Read SEC document |
| September 16, 2013 Filed Sep 17, 2013 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,085 | $76.40 | $235,694.00 |
DisclosureSEC source: 0001209191-13-044599 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,815 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $76.40 (range $75.97 to $76.93). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 16, 2013 Filed Sep 17, 2013 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $18.93 | $141,975.00 |
DisclosureSEC source: 0001209191-13-044599 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2013 Filed Aug 19, 2013 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-13-041331 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 7,500 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| August 15, 2013 Filed Aug 19, 2013 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,000 | $77.93 | $233,790.00 |
DisclosureSEC source: 0001209191-13-041331 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,400 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $77.93 (range $77.67 to $78.21). Read SEC document |
| August 15, 2013 Filed Aug 19, 2013 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,500 | $77.06 | $346,770.00 |
DisclosureSEC source: 0001209191-13-041331 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,400 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $77.06 (range $76.69 to $77.66). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 15, 2013 Filed Aug 19, 2013 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $18.93 | $141,975.00 |
DisclosureSEC source: 0001209191-13-041331 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 34,000 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-13-038688 · doc4.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2023-07-29 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-13-037015 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 7,500 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,535 | $86.66 | $219,683.10 |
DisclosureSEC source: 0001209191-13-037015 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,400 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $86.66 (range $86.38 to $87.33). Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,965 | $86.17 | $427,834.05 |
DisclosureSEC source: 0001209191-13-037015 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,935 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $86.17 (range $85.97 to $86.35). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2013 Filed Jul 17, 2013 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $18.93 | $141,975.00 |
DisclosureSEC source: 0001209191-13-037015 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · derivative · entry 11 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 7,500 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 9,800 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · derivative · entry 10 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,800 shares Expires 2013-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 105,000 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · derivative · entry 9 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 105,000 shares Expires 2019-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 39,365 | $80.58 | $3,172,031.70 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · nonDerivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,400 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $80.58 (range $80.04 to $81.02). Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 68,985 | $79.52 | $5,485,687.20 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · nonDerivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,765 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $79.52 (range $79.03 to $80.02). Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 13,950 | $78.94 | $1,101,213.00 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,750 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $78.94 (range $78.82 to $79.02). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $18.93 | $141,975.00 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 9,800 | $16.32 | $159,936.00 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 105,000 | $33.00 | $3,465,000.00 |
DisclosureSEC source: 0001209191-13-035485 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2013 Filed May 20, 2013 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftCommon Stock | 10,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-027552 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by GRATS Disclosed balance after: 0 F1 · ownership.nature: On May 16, 2013, grantor retained annuity trusts (GRATS) established by Dr. Mueller in 2010 that held 15,920 shares of common stock terminated in accordance with the terms of the GRATs. 10,352 shares were transferred to a trust established for the benefit of Dr. Mueller's adult child. The remaining 5,568 shares were distributed to revocable trusts established for the benefit of Dr. Mueller and his wife and are reported on this Form 4 as indirectly owned. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 54,375 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007128 · doc4.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0001209191-13-007128 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,400 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| October 15, 2012 Filed Oct 16, 2012 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option Grant (right to buy) · Derivative | 6,500 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001209191-12-049586 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 Underlying: Common Stock · 6,500 shares Expires 2013-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| October 15, 2012 Filed Oct 16, 2012 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,000 | $53.14 | $106,280.00 |
DisclosureSEC source: 0001209191-12-049586 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,316 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $53.14 (range $53.00 to $53.91). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.